

Review Article

How Should Antibodies against *P. falciparum* Merozoite Antigens Be Measured?

Sriwipa Chuangchaiya and Kristina E. M. Persson

Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Nobels väg 16, 17177 Stockholm, Sweden

Correspondence should be addressed to Kristina E. M. Persson; kristina.persson@ki.se

Received 14 November 2012; Revised 1 April 2013; Accepted 2 April 2013

Academic Editor: Aditya Prasad Dash

Copyright © 2013 S. Chuangchaiya and K. E. M. Persson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Immunity against malaria develops slowly and only after repeated exposure to the parasite. Many of those that die of the disease are children under five years of age. Antibodies are an important part of immunity, but which antibodies that are protective and how these should be measured are still unclear. We discuss the pros and cons of ELISA, invasion inhibition assays/ADCI, and measurement of affinity of antibodies and what can be done to improve these assays, thereby increasing the knowledge about the immune status of an individual, and to perform better evaluation of vaccine trials.

1. Introduction

Malaria kills around one million people every year [1, 2]. There is no vaccine against the disease, and resistance against medications is increasing. The symptoms of malaria include fever and anemia, and most of the deaths are caused by the parasite *Plasmodium falciparum*. The merozoite form of the parasite invades red cells, grows to form ring-, trophozoite- and schizont stages, and after rupture of the infected red cell new merozoites are released that are ready to enter uninfected red cells.

Merozoite invasion is a process that takes only a few minutes [3], but it involves several complex receptor-ligand interactions. Initial attachment of the merozoite is mediated by merozoite surface proteins such as MSP1 and MSP2, and is followed by reorientation of the merozoite where apical membrane antigen 1 (AMA1) is of importance [4, 5]. Other ligands such as erythrocyte-binding antigens (EBAs), for example, EBA140, EBA175, and EBA181 and *P. falciparum* reticulocyte-binding homologues (PfRh), including PfRh1, PfRh2, PfRh4, and PfRh5 have also shown to be involved in the invasion process [6–9], even though the exact function of each antigen is not known. Genetic polymorphisms exist for

many of the above-mentioned ligands, and based on some genes like MSP2, parasites can be grouped into two major allelic types: 3D7 and FC27. Serine repeat antigens (SERAs) are proteases that take part in forming a protein complex that is associated with the merozoite surface [10–12], and entry into the red blood cell is finally completed by an actin-myosin motor movement [13, 14].

Individuals who live in malaria endemic areas eventually develop immunity, but only slowly and after repeated exposure [15, 16]. Many of those that die of malaria are small children. During pregnancy, women have a greater risk of succumbing to malaria, and the fetus is also at risk [17]. Immunity against severe disease often develops before complete immunity is formed. It is known that antibodies are important in the defence against malaria, and it has been shown that passive transfer of antibodies from immune donors to individuals with *P. falciparum* infection reduces parasitemia and clears clinical symptoms [18–21]. However, exactly which specific antibodies are protective against future disease are not yet defined, and how they should be measured is even less clear. This information is urgently needed to be able to develop a functioning vaccine, something that has so far failed. We will here discuss the pros and cons for different

methods available such as ELISA, invasion inhibition assays (IIAs), antibody-dependent cellular inhibition (ADCI), and affinity, and we compare it to measurements of antibodies in other diseases and how the overall evaluation of immunity or vaccine status of malaria could possibly be improved.

2. ELISA

When antibodies directed against different *P. falciparum* antigens have been measured, ELISA has usually been the method of choice. In this static method, proteins are coated to a plate and levels of antibodies in plasma from patients with (or without) malaria can be estimated. When recombinant proteins are used, only antibodies directed against specific antigens are analyzed. In real life, the antigen of choice is located together with several other antigens, for example, on the merozoite surface, and there might be interaction or competition between binding of different antibodies, something that is not accounted for in an ELISA. It has, for example, been shown for MSP1 that there are blocking antibodies that can compete with the binding of cleavage-inhibiting antibodies for epitopes on the merozoite [22, 23], and there are also other studies that have demonstrated that mixing of different antibodies can influence the outcome of the assay [24]. This kind of studies indicates that we should more look at using assays where the function of antibodies is studied, but the reason for why ELISAs are continued to be used to such a major extent is probably that they are very easy, fast, and robust to perform compared to functional assays.

When recombinant proteins are applied in ELISAs, the result might depend on which part of an antigen that is selected for use in the assay. For MSP1, it has been shown that antibodies against MSP1-19 were associated with some protection, while antibodies against MSP1 block-1 were not [25]. However, even when the same subdomain has been used such as in studies of EBA175, contradictory results have been achieved for whether there was a protective effect of antibodies or not [26, 27]. When red cells burst due to egress of merozoites, a lot of “debris” will be left in the blood stream that needs to be removed, and many of the antibodies might help in doing this but this does not mean that the antibodies will protect from future disease. If only ELISAs are used, it is difficult to discern which antibodies are functionally important.

In general, higher levels of antibodies are found in ELISAs in older individuals in endemic areas, while lower levels of antibodies are seen in younger individuals in the same areas. This was recently shown for the EBAs for example [28] and it has been shown earlier for other antigens as well [7, 26, 27, 29, 30]. However, even though an individual has high levels of antibodies, they can still develop malaria, and an individual with relatively low levels of antibodies can be fully protected from clinical and severe malaria [25, 31–52]. In vaccine trials, antibodies measured by ELISA have been shown to often be short-lived, and most patients will still get malaria in spite of presence of antigen-specific antibodies [53]. From a population perspective, ELISAs can be used to make an overall estimation of how much exposure there has been to malaria, but for each individual it is not possible

to make an exact determination of the immune status. The only thing that can for sure be concluded from a positive response in ELISA is that the individual has at some stage during his/her lifetime been exposed to malaria.

When ELISAs against different antigens are combined, more information can possibly be acquired about the level of immunity in investigations of the breadth of antibodies [27], but the question of whether it is just a measure of exposure will still remain. A way of improving the ELISAs would be to more often use standardized controls, allowing for the measurement of exact amounts of specific antibodies instead of titers.

In conclusion, ELISAs are easy and robust to perform, and they can clearly give us information about whether or not an individual has ever been exposed to malaria. With combinations of different antigens and standardization of the assays, more information can possibly be provided. However, ELISAs do not tell us anything about the function of the antibodies, and on an individual level, ELISAs will not give us complete information about immunity.

3. Growth Inhibition Assay/Invasion Inhibition Assay

One assay that has been used to try and better determine the function of antibodies in plasma is growth inhibition assay or invasion inhibition assay (IIA). Antibodies directed against merozoite antigens are thought to function by directly inhibiting invasion of new red cells, which will then stop further multiplication of parasites, or through ADCI. By adding immune plasma, which contains antibodies to growing parasites, the inhibitory function of the antibodies can be evaluated in comparison to parasites where no plasma has been added. The downside of IIAs compared to ELISAs is that they are much more labor intensive, but on the other hand all proteins are expressed in their native environment and many both known and unknown potential interacting factors are included in the assay. There have been several studies that have shown invasion inhibitory activity of antibodies from human plasma, both when total IgG has been used and when malaria-antigen-specific fractions have been used [22, 54–58]. Some studies have shown increasing invasion inhibition with age [59] while others have shown more invasion inhibition in children [56, 60]. This kind of contradictory results might be explained by different functions in the antibodies repertoire being important during development of immunity, compared to when immunity is already established, but it might also mean that the assay is not yet fully optimized to show who is immune or not. One attempt to improve the IIA is by adding monocytes (ADCI). When ADCI has been employed, some antigens like MSP3 and GLURP [61, 62] have shown an inhibitory effect only when monocytes were included in the IIA. However, with ADCI there seems to be a major variability in the assay that can be seen from day to day even using the same donor of monocytes, making it difficult to standardize the assay [63]. If this assay could be improved and standardized, it might add very valuable information about different antibodies.




FIGURE 1: In a study of children with mild malaria in Uganda, IIA of a wild isolate was compared to ELISA using MSP2-3D7 as antigen $R^2 = 0.07$.

Another attempt to try and improve IIA is to use knock-out lines of parasites. Here, a single antigen can be studied in its natural environment and with the correctly folded protein, and a comparison can be made between the wild-type and the knockout parasites. This has been used, for example, for the EBAs, where it was shown that antibodies against EBA175 was responsible for a major part of the inhibitory activity in some individual plasma samples, while other samples seemed not to have any functional antibodies against this protein at all [29]. This kind of results is important for selection of potential vaccine candidates, especially for ruling out those antibodies that have no effect. Some antigens have been difficult to knock out, in which case other reagents might have to be added to the assay such as blocking agents, to find out which antibodies are causing the inhibitory effect.

In conclusion, IIAs are labor intensive but can provide important information especially for comparisons between knockout and wild-type parasites, where the function of a single potential vaccine candidate antigen can be evaluated.

4. Affinity

Another way of looking at antibodies against merozoite antigens is to study the affinity/avidity of antibodies. Some studies have tried to use ELISA with added NH_4SCN to evaluate affinity, but the results for this have been inconsistent [64, 65]. A new way of investigating affinity for vaccine trials has opened up with methods like surface plasmon resonance (SPR) [66, 67], where affinity of antibodies can be estimated under flow, something that ought to be more similar to the physiological situation compared to static assays. With this method, association and dissociation of antibodies binding to their target antigens can be studied in real time. This method has before mainly been used with monoclonal antibodies in malaria research, but it has recently been applied also to polyclonal antibodies. It has, for example, been shown that affinity of antibodies against AMA1 increased with age, and the presence of high affinity antibodies in plasma against MSP2-3D7 was associated with protection against malaria [68]. In this study, most plasma samples showed a relatively

rapid on-rate, indicating that whether the concentration of antibodies in the samples is high or low, the antibodies will still bind quite fast to their antigens. This is important for considering whether an antibody will function in inhibiting merozoite invasion or not, since invasion is a process that takes only a couple of minutes. The dissociation rate (which is concentration independent) might therefore be more important for whether an antibody will function or not. In the referred study, monoclonal antibodies were also used and it could be seen that some bound with so low dissociation rates, that a value for the dissociation rate could not be obtained. These antibodies will probably have difficulties in inhibiting invasion. However, investigations of affinity of antibodies in malaria are yet a very new field which needs a lot more studies to be able to make firm conclusions, and standardized protocols needs to be in place to facilitate interpretation of the results. In other infectious diseases, such as bacterial diseases [69, 70], toxoplasma [71], or HIV [72], a lot more has been done in the field of affinity.

In conclusion, studies of affinity of polyclonal antibodies in malaria is a new field that could add a lot of information both about how immunity is formed and for vaccine trials, and more work in this area is needed.

5. Comparing Different Ways of Measuring Antibodies

When different assays are used to evaluate antibodies against malaria, the methods often show results that do not correlate with each other. For example, SPR has been shown to correlate with ELISA for AMA1, which binds with relatively high affinity, but not for MSP2, which binds with lower affinity [68]. When IIA has been compared to ELISA, some people have shown correlations while others have not seen any correlations [36, 73]. This is probably because IIA is a functional assay, while ELISA only estimates the levels of antibodies. An example of the lack of major correlations between methods (IIA and ELISA) is shown in Figure 1. This illustrates the difficulties in estimating immunity against malaria. For vaccine trials, one has to be careful with interpretation of results, as the results could vary a lot depending on which method is used. In other fields such as HIV, international consortia have established common standards to be used in immunological assays, and this might be applicable for ELISAs, but more challenging for the functional methods yet available in malaria.

6. Which Method Should We Use to Measure Antibodies against Malaria?

None of the methods described here are good enough on their own to give a complete picture of an individual's immune status. ELISAs are good at giving us information about whether any immune response at all is mounted against a potential vaccine candidate, and from a population perspective when many samples need to be analyzed, ELISAs are easy to perform. However, if we want to know something about the function of a specific antibody, IIA with the usage

of knockout and wild-type parasites should be the way forward. Even though these assays are more cumbersome to perform, they will add valuable information. Affinity of antibodies has so far been very scarcely studied in malaria research compared to many other diseases, and expansion of this field should add important information both for knowledge about immunity and for vaccine trials. More studies are needed that employ different methods together in the same patient cohorts to get a more full picture of which functions of antibodies are important during different stages of development of immunity against malaria.

In conclusion, which method should be used depends on what we want to know about the antibodies. If we only want to know whether antibodies are formed or not, ELISAs can be used, but if we want to know something about the function of the antibodies, more elaborate assays such as IIA have to be applied. To get the full picture about immunity status in an individual, the methods available have to be developed more and probably combined to a bigger extent, but with new methods such as those available for affinity measurements there is hope that this situation can be improved.

Acknowledgments

This work has been supported by Vinnova, Sida, MSB, and Svenska Läkaresällskapet.

References

- [1] WHO, *World Malaria Report 2012*, World Health Organization, Geneva, Switzerland, 2012.
- [2] C. J. Murray, L. C. Rosenfeld, S. S. Lim et al., "Global malaria mortality between 1980 and 2010: a systematic analysis," *The Lancet*, vol. 379, no. 9814, pp. 413–431, 2012.
- [3] P. R. Gilson and B. S. Crabb, "Morphology and kinetics of the three distinct phases of red blood cell invasion by *Plasmodium falciparum* merozoites," *International Journal for Parasitology*, vol. 39, no. 1, pp. 91–96, 2009.
- [4] E. J. Remarque, B. W. Faber, C. H. M. Kocken, and A. W. Thomas, "Apical membrane antigen 1: a malaria vaccine candidate in review," *Trends in Parasitology*, vol. 24, no. 2, pp. 74–84, 2008.
- [5] J. S. Tyler, M. Treeck, and J. C. Boothroyd, "Focus on the ringleader: the role of AMA1 in apicomplexan invasion and replication," *Trends in Parasitology*, vol. 27, no. 9, pp. 410–420, 2011.
- [6] K. L. Harvey, P. R. Gilson, and B. S. Crabb, "A model for the progression of receptor-ligand interactions during erythrocyte invasion by *Plasmodium falciparum*," *International Journal For Parasitology*, vol. 42, no. 6, pp. 567–573, 2012.
- [7] J. Baum, A. G. Maier, R. T. Good, K. M. Simpson, and A. F. Cowman, "Invasion by *P. falciparum* merozoites suggests a hierarchy of molecular interactions," *PLoS Pathogens*, vol. 1, no. 4, article e37, 2005.
- [8] A. F. Cowman and B. S. Crabb, "Invasion of red blood cells by malaria parasites," *Cell*, vol. 124, no. 4, pp. 755–766, 2006.
- [9] L. H. Miller, D. I. Baruch, K. Marsh, and O. K. Doumbo, "The pathogenic basis of malaria," *Nature*, vol. 415, no. 6872, pp. 673–679, 2002.
- [10] X. L. Pang, T. Mitamura, and T. Horii, "Antibodies reactive with the N-terminal domain of *Plasmodium falciparum* serine repeat antigen inhibit cell proliferation by agglutinating merozoites and schizonts," *Infection and Immunity*, vol. 67, no. 4, pp. 1821–1827, 1999.
- [11] E. D. Putrianti, A. Schmidt-Christensen, I. Arnold, V. T. Heussler, K. Matuschewski, and O. Silvie, "The Plasmodium serine-type SERA proteases display distinct expression patterns and non-essential in vivo roles during life cycle progression of the malaria parasite," *Cellular Microbiology*, vol. 12, no. 6, pp. 725–739, 2010.
- [12] P. J. Rosenthal, "Falcipains and other cysteine proteases of malaria parasites," *Advances in Experimental Medicine and Biology*, vol. 712, pp. 30–48, 2011.
- [13] S. H. I. Kappe, C. A. Buscaglia, L. W. Bergman, I. Coppens, and V. Nussenzweig, "Apicomplexan gliding motility and host cell invasion: overhauling the motor model," *Trends in Parasitology*, vol. 20, no. 1, pp. 13–16, 2004.
- [14] E. S. Zuccala and J. Baum, "Cytoskeletal and membrane remodelling during malaria parasite invasion of the human erythrocyte," *British Journal of Haematology*, vol. 154, no. 6, pp. 680–689, 2011.
- [15] J. K. Baird, T. R. Jones, E. W. Danudirgo et al., "Age-dependent acquired protection against *Plasmodium falciparum* in people having two years exposure to hyperendemic malaria," *The American Journal of Tropical Medicine and Hygiene*, vol. 45, no. 1, pp. 65–76, 1991.
- [16] K. Marsh and S. Kinyanjui, "Immune effector mechanisms in malaria," *Parasite Immunology*, vol. 28, no. 1-2, pp. 51–60, 2006.
- [17] J. Schantz-Dunn and N. M. Nour, "Malaria pregnancy: a global health perspective," *Reviews in Obstetrics and Gynecology*, vol. 2, no. 3, pp. 186–192, 2009.
- [18] S. Cohen, I. A. McGregor, and S. Carrington, "Gamma-globulin and acquired immunity to human malaria," *Nature*, vol. 192, no. 4804, pp. 733–737, 1961.
- [19] M. Hommel and S. Semoff, "Expression and function of erythrocyte-associated surface antigens in malaria," *Biology of the Cell*, vol. 64, no. 2, pp. 183–203, 1988.
- [20] M. Mayxay, K. Chotivanich, S. Pukrittayakamee, P. Newton, S. Looareesuwan, and N. J. White, "Contribution of humoral immunity to the therapeutic response in falciparum malaria," *The American Journal of Tropical Medicine and Hygiene*, vol. 65, no. 6, pp. 918–923, 2001.
- [21] H. Bouharoun-Tayoun, P. Attanath, A. Sabchareon, T. Chongsuphajaisiddhi, and P. Druilhe, "Antibodies that protect humans against *Plasmodium falciparum* blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes," *Journal of Experimental Medicine*, vol. 172, no. 6, pp. 1633–1641, 1990.
- [22] A. F. Egan, P. Burghaus, P. Druilhe, A. A. Holder, and E. M. Riley, "Human antibodies to the 19 kDa C-terminal fragment of *Plasmodium falciparum* merozoite surface protein 1 inhibit parasite growth in vitro," *Parasite Immunology*, vol. 21, no. 3, pp. 133–139, 1999.
- [23] J. A. Guevara Patiño, A. A. Holder, J. S. McBride, and M. J. Blackman, "Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies," *Journal of Experimental Medicine*, vol. 186, no. 10, pp. 1689–1699, 1997.
- [24] R. Moreno, F. Pörtl-Frank, D. Stüber et al., "Rhoptry-associated protein 1-binding monoclonal antibody raised against a heterologous peptide sequence inhibits *Plasmodium falciparum*

- growth in vitro," *Infection and Immunity*, vol. 69, no. 4, pp. 2558–2568, 2001.
- [25] F. J. I. Fowkes, J. S. Richards, J. A. Simpson, and J. G. Beeson, "The relationship between anti-merozoite antibodies and incidence of *Plasmodium falciparum* malaria: a systematic review and meta-analysis," *PLoS Medicine*, vol. 7, no. 1, Article ID e1000218, 2010.
- [26] D. M. N. Okenu, E. M. Riley, Q. D. Bickle et al., "Analysis of human antibodies to erythrocyte binding antigen 175 of *Plasmodium falciparum*," *Infection and Immunity*, vol. 68, no. 10, pp. 5559–5566, 2000.
- [27] F. H. A. Osier, G. Fegan, S. D. Polley et al., "Breadth and magnitude of antibody responses to multiple *Plasmodium falciparum* merozoite antigens are associated with protection from clinical malaria," *Infection and Immunity*, vol. 76, no. 5, pp. 2240–2248, 2008.
- [28] J. S. Richards, D. I. Stanisic, F. J. I. Fowkes et al., "Association between naturally acquired antibodies to erythrocyte-binding antigens of *Plasmodium falciparum* and protection from malaria and high-density parasitemia," *Clinical Infectious Diseases*, vol. 51, no. 8, pp. e50–e60, 2010.
- [29] K. E. M. Persson, F. J. McCallum, L. Reiling et al., "Variation in use of erythrocyte invasion pathways by *Plasmodium falciparum* mediates evasion of human inhibitory antibodies," *Journal of Clinical Investigation*, vol. 118, no. 1, pp. 342–351, 2008.
- [30] L. Ford, C. A. Lobo, M. Rodriguez et al., "Differential antibody responses to *Plasmodium falciparum* invasion ligand proteins in individuals living in malaria-endemic areas in Brazil and Cameroon," *The American Journal of Tropical Medicine and Hygiene*, vol. 77, no. 5, pp. 977–983, 2007.
- [31] F. Al-Yaman, B. Genton, R. Anders et al., "Assessment of the role of the humoral response to *Plasmodium falciparum* MSP2 compared to RESA and Spf66 in protecting Papua New Guinea children from clinical malaria," *Parasite Immunology*, vol. 17, no. 9, pp. 493–501, 1995.
- [32] F. Al-Yaman, B. Genton, R. F. Anders et al., "Relationship between humoral response to *Plasmodium falciparum* merozoite surface antigen-2 and malaria morbidity in a highly endemic area of Papua New Guinea," *The American Journal of Tropical Medicine and Hygiene*, vol. 51, no. 5, pp. 593–602, 1994.
- [33] F. Al-Vaman, B. Genton, K. J. Kramer et al., "Acquired antibody levels to *Plasmodium falciparum* merozoite surface antigen 1 in residents of a highly endemic area of Papua New Guinea," *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 89, no. 5, pp. 555–559, 1995.
- [34] A. Dent, I. Malhotra, P. Mungai et al., "Prenatal malaria immune experience affects acquisition of *Plasmodium falciparum* merozoite surface protein-1 invasion inhibitory antibodies during infancy," *Journal of Immunology*, vol. 177, no. 10, pp. 7139–7145, 2006.
- [35] D. Doodoo, F. Atuguba, S. Bosomprah et al., "Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana," *Malaria Journal*, vol. 10, article 108, 2011.
- [36] C. C. John, R. A. O'Donnell, P. O. Sumba et al., "Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-119) can play a protective role against blood-stage *Plasmodium falciparum* infection in individuals in a malaria endemic area of Africa," *Journal of Immunology*, vol. 173, no. 1, pp. 666–672, 2004.
- [37] K. A. Kusi, D. Doodoo, S. Bosomprah et al., "Measurement of the plasma levels of antibodies against the polymorphic vaccine candidate apical membrane antigen 1 in a malaria-exposed population," *BMC Infectious Diseases*, vol. 12, article 32, 2012.
- [38] S. D. Polley, T. Mwangi, C. H. M. Kocken et al., "Human antibodies to recombinant protein constructs of *Plasmodium falciparum* Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria," *Vaccine*, vol. 23, no. 5, pp. 718–728, 2004.
- [39] K. Marsh and R. W. Snow, "Host-parasite interaction and morbidity in malaria endemic areas," *Philosophical Transactions of the Royal Society B*, vol. 352, no. 1359, pp. 1385–1394, 1997.
- [40] D. Doodoo, T. G. Theander, J. A. L. Kurtzhals et al., "Levels of antibody to conserved parts of *Plasmodium falciparum* merozoite surface protein I in Ghanaian children are not associated with protection from clinical malaria," *Infection and Immunity*, vol. 67, no. 5, pp. 2131–2137, 1999.
- [41] D. Doodoo, A. Aikins, K. A. Kusi et al., "Cohort study of the association of antibody levels to AMA1, MSP1 19, MSP3 and GLURP with protection from clinical malaria in Ghanaian children," *Malaria Journal*, vol. 7, article 142, 2008.
- [42] E. M. Braga, R. M. Barros, T. A. Reis et al., "Association of the IgG response to *Plasmodium falciparum* merozoite protein (C-terminal 19 kD) with clinical immunity to malaria in the Brazilian Amazon region," *The American Journal of Tropical Medicine and Hygiene*, vol. 66, no. 5, pp. 461–466, 2002.
- [43] S. Soe, M. Theisen, C. Roussillon, Khin-Saw-Aye, and P. Druilhe, "Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein," *Infection and Immunity*, vol. 72, no. 1, pp. 247–252, 2004.
- [44] V. Meraldi, I. Nebié, A. B. Tiono et al., "Natural antibody response to *Plasmodium falciparum* Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection," *Parasite Immunology*, vol. 26, no. 6–7, pp. 265–272, 2004.
- [45] A. F. Egan, J. Morris, G. Barnish et al., "Clinical immunity to *Plasmodium falciparum* malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1," *Journal of Infectious Diseases*, vol. 173, no. 3, pp. 765–769, 1996.
- [46] W. G. Metzger, D. M. N. Okenu, D. R. Cavanagh et al., "Serum IgG3 to the *Plasmodium falciparum* merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria," *Parasite Immunology*, vol. 25, no. 6, pp. 307–312, 2003.
- [47] S. D. Polley, K. K. A. Tetteh, D. R. Cavanagh et al., "Repeat sequences in block 2 of *Plasmodium falciparum* merozoite surface protein 1 are targets of antibodies associated with protection from malaria," *Infection and Immunity*, vol. 71, no. 4, pp. 1833–1842, 2003.
- [48] I. Nebie, A. B. Tiono, D. A. Diallo et al., "Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?" *Tropical Medicine and International Health*, vol. 13, no. 2, pp. 229–237, 2008.
- [49] J. P. A. Lusingu, L. S. Vestergaard, M. Alifrangis et al., "Cytophilic antibodies to *Plasmodium falciparum* Glutamate Rich Protein are associated with malaria protection in an area of holoendemic transmission," *Malaria Journal*, vol. 4, article 48, 2005.

- [50] D. I. Stanisic, J. S. Richards, F. J. McCallum et al., "Immunoglobulin G subclass-specific responses against *Plasmodium falciparum* merozoite antigens are associated with control of parasitemia and protection from symptomatic illness," *Infection and Immunity*, vol. 77, no. 3, pp. 1165–1174, 2009.
- [51] I. Nebie, A. Diarra, A. Ouedraogo et al., "Humoral responses to *Plasmodium falciparum* blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa," *Infection and Immunity*, vol. 76, no. 2, pp. 759–766, 2008.
- [52] M. Dziegiel, P. Rowe, S. Bennett et al., "Immunoglobulin M and G antibody responses to *Plasmodium falciparum* glutamate-rich protein: correlation with clinical immunity in Gambian children," *Infection and Immunity*, vol. 61, no. 1, pp. 103–108, 1993.
- [53] S. Abdulla, N. Salim, F. Machera et al., "Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS, S/AS02(D) malaria vaccine in infants living in a malaria-endemic region," *Malaria Journal*, vol. 12, article 11, 2013.
- [54] A. Bolad, I. Nebié, N. Cuzin-Ouattara, A. Traore, F. Esposito, and K. Berzins, "Antibody-mediated in vitro growth inhibition of field isolates of *Plasmodium falciparum* from asymptomatic children in Burkina Faso," *The American Journal of Tropical Medicine and Hygiene*, vol. 68, no. 6, pp. 728–733, 2003.
- [55] A. N. Hodder, P. E. Crewther, and R. F. Anders, "Specificity of the protective antibody response to apical membrane antigen 1," *Infection and Immunity*, vol. 69, no. 5, pp. 3286–3294, 2001.
- [56] F. J. McCallum, K. E. M. Persson, C. K. Mugenyi et al., "Acquisition of growth-inhibitory antibodies against blood-stage *Plasmodium falciparum*," *PLoS ONE*, vol. 3, no. 10, Article ID e3571, 2008.
- [57] E. E. H. Murhandarwati, L. Wang, C. G. Black, H. N. Doan, T. L. Richie, and R. L. Coppel, "Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with *Plasmodium falciparum* in semi-immune individuals in Vietnam," *Infection and Immunity*, vol. 77, no. 10, pp. 4510–4517, 2009.
- [58] R. Perrant, L. Marrama, B. Diouf et al., "Antibodies to the conserved C-terminal domain of the *Plasmodium falciparum* merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village," *Journal of Infectious Diseases*, vol. 191, no. 2, pp. 264–271, 2005.
- [59] P. D. Crompton, K. Miura, B. Traore et al., "In vitro growth-inhibitory activity and malaria risk in a cohort study in Mali," *Infection and Immunity*, vol. 78, no. 2, pp. 737–745, 2010.
- [60] A. E. Dent, K. Chelimo, P. O. Sumba et al., "Temporal stability of naturally acquired immunity to merozoite surface protein-1 in Kenyan adults," *Malaria Journal*, vol. 8, no. 1, article 162, 2009.
- [61] P. Druilhe, F. Spertini, D. Soesoe et al., "A malaria vaccine that elicits in humans antibodies able to kill *Plasmodium falciparum*," *PLoS Medicine*, vol. 2, no. 11, Article ID e344, pp. 1135–1144, 2005.
- [62] M. Theisen, S. Soe, C. Oeuvray et al., "The glutamate-rich protein (GLURP) of *Plasmodium falciparum* is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro," *Infection and Immunity*, vol. 66, no. 1, pp. 11–17, 1998.
- [63] Y. P. Shi, V. Udhayakumar, A. J. Oloo, B. L. Nahlen, and A. A. Lal, "Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage *Plasmodium falciparum* parasites," *The American Journal of Tropical Medicine and Hygiene*, vol. 60, no. 1, pp. 135–141, 1999.
- [64] D. Y. Bargieri, D. S. Rosa, M. A. S. Lasaro, L. C. S. Ferreira, I. S. Soares, and M. M. Rodrigues, "Adjuvant requirement for successful immunization with recombinant derivatives of *Plasmodium vivax* merozoite surface protein-1 delivered via the intranasal route," *Memorias do Instituto Oswaldo Cruz*, vol. 102, no. 3, pp. 313–317, 2007.
- [65] M. U. Ferreira and A. M. Katzin, "The assessment of antibody affinity distribution by thiocyanate elution: a simple dose-response approach," *Journal of Immunological Methods*, vol. 187, no. 2, pp. 297–305, 1995.
- [66] S. Hearty, P. J. Conroy, B. V. Ayyar, B. Byrne, and R. O'Kennedy, "Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends," *Expert Review of Vaccines*, vol. 9, no. 6, pp. 645–664, 2010.
- [67] R. M. Wohlhueter, K. Parekh, V. Udhayakumar, S. Fang, and A. A. Lal, "Analysis of binding of monoclonal antibody to a malarial peptide by surface plasmon resonance biosensor and integrated rate equations," *Journal of Immunology*, vol. 153, no. 1, pp. 181–189, 1994.
- [68] S. B. Reddy, R. F. Anders, J. G. Beeson et al., "High affinity antibodies to *Plasmodium falciparum* merozoite antigens are associated with protection from malaria," *PLoS One*, vol. 7, no. 2, Article ID e32242, 2012.
- [69] M. A. Breukels, E. M. Jol-Van der Zijde, M. J. D. Van Tol, and G. T. Rijkers, "Concentration and avidity of anti-Haemophilus influenzae type b (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed," *Clinical Infectious Diseases*, vol. 34, no. 2, pp. 191–197, 2002.
- [70] D. Goldblatt, A. R. J. P. M. Pinto Vaz, and E. Miller, "Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization," *Journal of Infectious Diseases*, vol. 177, no. 4, pp. 1112–1115, 1998.
- [71] J. S. Remington, P. Thulliez, and J. G. Montoya, "Recent developments for diagnosis of toxoplasmosis," *Journal of Clinical Microbiology*, vol. 42, no. 3, pp. 941–945, 2004.
- [72] H. Mouquet and M. C. Nussenzweig, "Polyreactive antibodies in adaptive immune responses to viruses," *Cellular and Molecular Life Sciences*, vol. 69, no. 9, pp. 1435–1445, 2012.
- [73] J. Rono, A. Färnert, D. Olsson et al., "*Plasmodium falciparum* line-dependent association of in vitro growth-inhibitory activity and risk of malaria," *Infection and Immunity*, vol. 80, no. 5, pp. 1900–1908, 2012.